Changes in AIDS survival time in two San Francisco cohorts of homosexual men, 1983 to 1993

JAMA

Volumn 271, Issue 14, 1994, Pages 1083-1087

  Osmond, Dennis ^a,c   Charlebois, Edwin ^a   Lang, William ^b   Shiboski, Stephen ^a   Moss, Andrew ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^c SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; COHORT ANALYSIS; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPHYLAXIS; RISK FACTOR; SURVIVAL TIME;

EID: 0028215619     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.271.14.1083     Document Type: Article

References (28)

1. Bacchetti P, Osmond D, Chaisson RE, et al. Survival patterns of the first 500 patients with AIDS in San Francisco. J Infect Dis. 1988;157:104-147.
2. Lemp GF, Payne SF, Neal D, et al. Survival trends for patients with AIDS. JAMA. 1990;263: 402-400.
3. Seage GR, Landers S, Lamb GA, Epstein AM. Effect of changing patterns of care and duration of survival on the cost of treating the acquired immunodeficiency syndrome (AIDS). Am J Public Health. 1990;80:835-839.
4. Creagh-Kirk T, Doi P, Andrews E, et al. Survival experience among patients with AIDS receiving zidovudine. JAMA. 1988;260:3009-3015.
5. Moore RD, Hidalgo J, Sugland BW, Chaisson RE. Zidovudine and the natural history of the acquired immunodeficiency syndrome. N Engl J Med. 1991;324:1412-1416.
6. Fischl MA, Richman DD, Crieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med. 1987;317:185-191.
7. Schneider MME, Hoepelman AIM, Schattenkerk JKME, et al. A controlled trial of aerosolised pentamidine or trimethoprim-sulfamethoxazole as priroary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. N Engl J Med. 1992;327: 1836-1841.
8. Hardy WD, Feinberg J, Finkelstein DM, et al. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome. N Engl J Med. 1992;327:1842-1848.
9. Hamilton JD, Hartigan PA, Simberkoff MS, et al. A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection: results of the Veterans Affairs Cooperative Study. N Engl J Med. 1992; 326:437-443.
10. Aboulker J-P, Swart AM. Preliminary analysis of the Concorde trial. Lancet. 1993;341:889-890.
11. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report: Year-End Edition. In press.
12. Centers for Disease Control. 1993. revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep. 1992;41(RR-11):1-19.
13. Moss AR, Osmond D, Bacchetti P, et al. Risk factors for AIDS and HIV seropositivity in homosexual men. Am J Epidemiol. 1987;125:1035-1047.
14. Moss AR, Bacchetti P, Osmond D, et al. Seropositivity for HIV and the development of AIDS and AIDS related condition: three year follow up of the San Francisco General Hospital Cohort. BMJ. 1988;296:745-750.
15. Winkelstein W, Lyman DM, Padian N, et al. Sexual practices and risk of infection by the human immunodeficiency virus: the San Francisco Men's Health Study. JAMA. 1987;257:321-325.
16. Lang W, Anderson RE, Perkins H, et al. Clinical, immunologic, and serologic findings in men at risk for acquired immunodeficiency syndrome: the San Francisco Men's Health Study. JAMA. 1987: 257:326-330.
17. Centers for Disease Control. Revision of the case definition for acquired immunodeficiency syndrome for national reporting - United States. MMWR Morb Mortal Wkly Rep. 1987;34:373-375.
18. Lange N, Carlin BP, Gelfand AE. Hierarchical Bayes models for the progression of HIV infection using longitudinal CD4 T-cell numbers. J Am Stat Assoc. 1992;87:615-626.
19. Miller RG Jr, Gong G, Munoz A. Survival Analysis. New York, NY: John Wiley & Sons Inc; 1981.
20. SAS Institute Inc. SAS/STAT Guide for Personal Computers. Version 6. Cary, NC: SAS Institute Inc; 1987.
21. Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N Engl J Med. 1990;322:941-949.
22. Fischl MA, Parker CR, Pertinelli C, et al. A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome, N Engl J Med. 1990;323: 1090-1014.
23. Lundgren JD, Pedersen C, Clumeck N, et al, the AIDS in Europe Study Group Coordinating Center. Survival differences in European AIDS patients, 1979-89. In: Program and abstracts of the Ninth International Conference on AIDS; June 6-11, 1993; Berlin, Germany. Abstract WS-BO:1-3.
24. Chaisson RE, Kenly J, Richman DD, et al. Pneumocystis prophylaxis and survival in patients with advanced human immunodeficiency virus infection treated with zidovudine. Arch Intern Med. 1992; 152:2009-2013.
25. Phillips AN, Elford J, Sabin C, et al. Immunodeficiency and the risk of death in HIV infection. JAMA. 1992;268:2662-2666.
26. Lang W. Frailty selection and HIV. Lancet. 1989;1:1397.
27. Lui KJ, Darrow WW, Rutherford GW. A model based estimate of the mean incubation period for AIDS in homosexual men. Science. 1988;240:1333-1335.
28. Bacchetti P, Moss AR. Incubation period of AIDS in San Francisco. Nature. 1989;338:251-253.